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Background
Once-daily tiotropium is an effective and safe add-on
bronchodilator for asthmatic adults who remain sympto-
matic despite inhaled corticosteroid (ICS) treatment in
accordance with current international guidelines. Despite
the wide range of available therapy options, many adoles-
cents with asthma have disease that is sub-optimally
controlled.
Methods
This randomised, placebo-controlled, double-blind,
incomplete crossover study (NCT01122680) evaluated
the efficacy and safety of 5, 2.5 and 1.25 µg once-daily
(evening) tiotropium (via Respimat® Soft Mist™ Inhaler)
versus placebo in three 4-week treatment periods in ado-
lescents (aged 12-17 years) with symptomatic asthma
despite medium-dose ICS. The primary efficacy end
point was change in peak forced expiratory volume in
1 second within 3 hours post-dose (peak FEV1(0-3h))
assessed as a response (difference from baseline). Second-
ary end points included trough FEV1, FEV1 area under
the curve (AUC)(0-3h), peak expiratory flow (PEFam/pm)
responses and Asthma Control Questionnaire (ACQ)
score.
Results
Of 139 enrolled patients, 105 were randomised to receive
one of four treatment sequences. Peak FEV1(0-3h)
response was statistically significantly greater with 5 µg
tiotropium than placebo (difference from placebo: 113
±39 (SE) mL; p=0.0043). Trough FEV1 and FEV1 AUC(0-
3h) responses with 5 µg tiotropium were also significantly
higher versus placebo (p<0.0001 and p=0.0001, respec-
tively). A superior PEFam and PEFpm response was
observed with 5 µg tiotropium over placebo. Although
ACQ scores improved from baseline (2.091) with tiotro-
pium (5 µg, 1.287; 2.5 µg, 1.366; 1.25 µg, 1.189), they also
improved with placebo (1.371), which may be due to
the short duration of this study. Safety profile was
balanced across treatment groups, with the majority of
adverse events being mild to moderate in severity and no
dose-dependency observed.
Conclusion
This first study of tiotropium as add-on to ICS in
adolescents with symptomatic asthma demonstrates that
5 µg tiotropium is an effective and well-tolerated dose.
Authors’ details
1University Hospital Carl Gustav Carus, Technical University of Dresden,
Dresden, Germany. 2Boehringer Ingelheim Pharma GmbH and Co. KG,
Ingelheim am Rh, Germany. 3Vilnius University Hospital, Vilnius, Lithuania.
4Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der,
Germany. 5Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
6Private Practice, Rēzekne, Latvia. 7Clinical Research of the Ozarks, Columbia,
MO, USA.
Published: 28 February 2014
doi:10.1186/2045-7022-4-S1-O5
Cite this article as: Vogelberg et al.: O05 - Once-daily tiotropium in
adolescents with symptomatic asthma despite inhaled corticosteroid
treatment: a dose-ranging study. Clinical and Translational Allergy 2014
4(Suppl 1):O5.
1University Hospital Carl Gustav Carus, Technical University of Dresden,
Dresden, Germany
Full list of author information is available at the end of the article
Vogelberg et al. Clinical and Translational Allergy 2014, 4(Suppl 1):O5
http://www.ctajournal.com/content/4/S1/O5
© 2014 Vogelberg et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
